NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Long Term Debt Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual long term debt in 2023 was 105.6 Thousand CAD , down -46.45% from previous year.
NervGen Pharma Corp.'s latest quarterly long term debt in 2024 Q2 was 57.71 Thousand CAD , down 0.0% from previous quarter.
NervGen Pharma Corp. reported annual long term debt of 197.19 Thousand CAD in 2022, down 0.0% from previous year.
NervGen Pharma Corp. reported annual long term debt of - CAD in 2021, down 0.0% from previous year.
NervGen Pharma Corp. reported quarterly long term debt of 57.71 Thousand CAD for 2024 Q2, down 0.0% from previous quarter.
NervGen Pharma Corp. reported quarterly long term debt of 105.6 Thousand CAD for 2023 FY, down -46.45% from previous quarter.

Annual Long Term Debt Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Long Term Debt of NervGen Pharma Corp. (2023 - 2017)

Year	Long Term Debt	Long Term Debt Growth
2023	105.6 Thousand CAD	-46.45%
2022	197.19 Thousand CAD	0.0%
2021	- CAD	0.0%
2020	- CAD	0.0%
2019	- CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	81.83 Thousand CAD	0.0%
2024 Q2	57.71 Thousand CAD	0.0%
2023 FY	105.6 Thousand CAD	-46.45%
2023 Q3	129.01 Thousand CAD	-15.17%
2023 Q1	174.8 Thousand CAD	-11.35%
2023 Q2	152.08 Thousand CAD	-13.0%
2023 Q4	105.6 Thousand CAD	-18.15%
2022 Q1	- CAD	0.0%
2022 FY	197.19 Thousand CAD	0.0%
2022 Q2	240.96 Thousand CAD	0.0%
2022 Q4	197.19 Thousand CAD	-10.06%
2022 Q3	219.24 Thousand CAD	-9.02%
2021 Q1	- CAD	0.0%
2021 FY	- CAD	0.0%
2021 Q4	- CAD	0.0%
2021 Q3	- CAD	0.0%
2021 Q2	- CAD	0.0%
2020 FY	- CAD	0.0%
2020 Q2	- CAD	0.0%
2020 Q4	- CAD	0.0%
2020 Q3	- CAD	0.0%
2020 Q1	- CAD	0.0%
2019 Q1	- CAD	0.0%
2019 FY	- CAD	0.0%
2019 Q4	- CAD	0.0%
2019 Q3	- CAD	0.0%
2019 Q2	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q4	- CAD	0.0%
2017 FY	- CAD	0.0%

Peer Long Term Debt Comparison of NervGen Pharma Corp.

Name	Long Term Debt	Long Term Debt Difference
Arch Biopartners Inc.	703.92 Thousand CAD	84.998%
Covalon Technologies Ltd.	919.08 Thousand CAD	88.51%
Hemostemix Inc.	4.32 Million CAD	97.556%
Universal Ibogaine Inc.	1.73 Million CAD	93.923%
Kane Biotech Inc.	1.3 Million CAD	91.892%
MedMira Inc.	2.95 Million CAD	96.429%
Marvel Biosciences Corp.	1 Million CAD	89.44%
XORTX Therapeutics Inc.	- CAD	-Infinity%